APA (7th ed.) Citation

Yao, Y., Wang, Y., Yang, F., Wang, C., Mao, M., Gai, Q., . . . Wang, Y. (2022). Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma. CNS Neuroscience & Therapeutics, 28(7), 1033. https://doi.org/10.1111/cns.13835

Chicago Style (17th ed.) Citation

Yao, Yue‐Liang, et al. "Targeting AKT and CK2 Represents a Novel Therapeutic Strategy for SMO Constitutive Activation‐driven Medulloblastoma." CNS Neuroscience & Therapeutics 28, no. 7 (2022): 1033. https://doi.org/10.1111/cns.13835.

MLA (9th ed.) Citation

Yao, Yue‐Liang, et al. "Targeting AKT and CK2 Represents a Novel Therapeutic Strategy for SMO Constitutive Activation‐driven Medulloblastoma." CNS Neuroscience & Therapeutics, vol. 28, no. 7, 2022, p. 1033, https://doi.org/10.1111/cns.13835.